DALLAS, July 17, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring drug development company Keryx Biopharmaceuticals Inc. (Nasdaq:KERX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Keryx Biopharmaceuticals Inc. (Nasdaq:KERX) should be of particular interest to other drug manufacturers: Novartis AG (NYSE:NVS), AstraZeneca plc (NYSE:AZN), Abbott Laboratories (NYSE:ABT) and Merck & Co. Inc. (NYSE:MRK).
It is available at: http://www.beaconequity.com/i/KERX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Keryx Biopharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of drug therapies associated with renal diseases and cancer. Its lead drug compound candidate, called Zerenex, is under development in phase II clinical trials for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease (ESRD). KERX also develops an anti-cancer agent, called KRX-0401, which is in phase II clinical development for the treatment of various tumors.
Read and post on Twitter and top Stock Message Boards for these stocks and more, all in real-time: http://www.BoardCentral.com/
In the report, the analyst notes:
"If ultimately approved by the U.S. Food and Drug Administration (FDA), the market for KERX's drug candidate Zerenex could reach more than $1 billion at its market saturation...with the prospects of reaching commercialization reaching approximately 50% following successful completion of phase II.
"The Company announced on July 14 that it commenced phase I clinical trials to evaluate KRX-0401 (perifosine) as a single agent treatment for tumors in pediatric patients. On June 8, the Company announced favorable results of phase II studies of Zerenex."
To read the entire report visit: http://www.beaconequity.com/i/KERX
Join the fastest growing investment community at: http://www.stockhideout.com
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.